Company intelligence / Profile preview

Biocompatibles

Oxford, Connecticut, United Statesbiocomplabs.com ↗

Ownership: Private
Development stage: Commercial

Overview

Biocompatibles developed innovative biopolymer-based medical devices and controlled-release drug delivery systems. Its main commercial focus was on embolization therapies using compressible PVA microspheres and proprietary polymer technologies for targeted cancer treatment. The company also had a significant contact lens business until its sale in 2002. It was acquired by BTG plc in 2010, which itself was acquired by Boston Scientific in 2019. Its core technologies are now part of Boston Scientific's interventional oncology portfolio.

Therapeutic areas: OncologyCardiovascularOphthalmology
Modalities: DevicePolymer-drug conjugate therapy (drug-eluting beads)Small molecule (delivered via embolic microspheres and beads)Biologic (encapsulation technologies for biological agents)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Biocompatibles.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocompatibles.